Judith Honing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Judith Honing has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Massimilliano di Pietro
Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom
2 shared publications - Rebecca C. Fitzgerald
Early Cancer Institute, University of Cambridge, Cambridge, UK
2 shared publications - Adriaan Olivier
School of Clinical Medicine, University of Cambridge, Cambridge, UK
1 shared publication Anne-Marie Lydon
Early Cancer Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
1 shared publicationBas Weusten
Affiliations Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, Department of Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, The Netherlands
1 shared publicationChristian Zakian
Chair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 6 August 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (2) , 259-276
Tethered optoacoustic and optical coherence tomography capsule endoscopy for label-free assessment of Barrett’s oesophageal neoplasia
Endoscopic detection of oesophageal cancer (EC) often occurs late in disease development, leading to high mortality rates. Improved technologies are urgently needed for earlier EC detection. Here we research an endoscopic ultra-broadband acoustic detection scheme and introduce a 360-degree hybrid optoacoustic and optical coherence endoscopy to enable interrogation of surface and subsurface precancerous and cancerous features at a three-dimensional micrometre scale. In the following pilot tissue investigation, the dual-modal imaging features are assessed for classifying different mucosal types in Barrett’s oesophagus (BE)—a precursor of EC. We find that human lesions of different grades, such as metaplastic, dysplastic and cancerous mucosa, exhibit distinctly different imaging features that are unique to the hybrid modality. Based on these features, a classification system is developed and evaluated for identifying BE neoplasia. The results show accurate BE neoplasia detection due to the complementarity of the two imaging modalities. Therefore, this study highlights the ability of the new dual-modality feature set to improve the detection performance of any of the two modalities operating in stand-alone mode and enhance diagnostic accuracy.
- 6 August 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (2) , 259-276
Open AccessTethered optoacoustic and optical coherence tomography capsule endoscopy for label-free assessment of Barrett’s oesophageal neoplasia
Endoscopic detection of oesophageal cancer (EC) often occurs late in disease development, leading to high mortality rates. Improved technologies are urgently needed for earlier EC detection. Here we research an endoscopic ultra-broadband acoustic detection scheme and introduce a 360-degree hybrid optoacoustic and optical coherence endoscopy to enable interrogation of surface and subsurface precancerous and cancerous features at a three-dimensional micrometre scale. In the following pilot tissue investigation, the dual-modal imaging features are assessed for classifying different mucosal types in Barrett’s oesophagus (BE)—a precursor of EC. We find that human lesions of different grades, such as metaplastic, dysplastic and cancerous mucosa, exhibit distinctly different imaging features that are unique to the hybrid modality. Based on these features, a classification system is developed and evaluated for identifying BE neoplasia. The results show accurate BE neoplasia detection due to the complementarity of the two imaging modalities. Therefore, this study highlights the ability of the new dual-modality feature set to improve the detection performance of any of the two modalities operating in stand-alone mode and enhance diagnostic accuracy.
- Open Access
- 6 February 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101989
Barrett's esophagus screening: Current modalities, risk-based approaches, and future perspectives
- 6 February 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101989
Open AccessBarrett's esophagus screening: Current modalities, risk-based approaches, and future perspectives
- 23 January 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101983
Preface to special edition: Screening and Early diagnosis of upper gastrointestinal neoplastic lesions
- 23 January 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101983
Preface to special edition: Screening and Early diagnosis of upper gastrointestinal neoplastic lesions
- Open Access
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0287587
Adequacy of endoscopic recognition and surveillance of gastric intestinal metaplasia and atrophic gastritis: A multicentre retrospective study in low incidence countries
Background: Gastric atrophy (GA) and gastric intestinal metaplasia (GIM) are precursor conditions to gastric adenocarcinoma (GAC) and should be monitored endoscopically in selected individuals. However, little is known about adherence to recommendations in clinical practice in low-risk countries. Objective: The aim of this study was to evaluate endoscopic recognition and adequacy of surveillance for GA and GIM in countries with low GAC prevalence. Methods: We retrospectively analysed patients diagnosed with GIM or GA in three centers in The Netherlands and UK between 2012 and 2019. Cases with GIM and/or GA diagnosis at index endoscopy were retrieved through systematic search of pathology databases using ‘gastric’ and ‘intestinal metaplasia’ or ‘atrophy’ keywords. Endoscopy reports were analysed to ascertain accuracy of endoscopic diagnoses. Adequacy of surveillance was assessed following histological diagnosis at the index endoscopy based on ESGE guidelines published in 2012. Results: We included 396 patients with a median follow-up of 57.2 months. Mean age was 66 years and the rates of antrum-predominant versus extensive GIM were comparable (37% vs 38%). Endoscopic recognition rates were 48.5% for GA and 16.3% for GIM. Surveillance was adequately carried out in 215 of 396 patients (54.3%). Conclusion: In countries with a low incidence of GAC, the rate of endoscopic recognition of gastric pre-cancerous lesions and adherence to surveillance recommendation are low. Substantial improvement is required in endoscopic training and awareness of guidelines recommendation in order to optimise detection and management of pre-malignant gastric conditions.
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0287587
Open AccessAdequacy of endoscopic recognition and surveillance of gastric intestinal metaplasia and atrophic gastritis: A multicentre retrospective study in low incidence countries
Background: Gastric atrophy (GA) and gastric intestinal metaplasia (GIM) are precursor conditions to gastric adenocarcinoma (GAC) and should be monitored endoscopically in selected individuals. However, little is known about adherence to recommendations in clinical practice in low-risk countries. Objective: The aim of this study was to evaluate endoscopic recognition and adequacy of surveillance for GA and GIM in countries with low GAC prevalence. Methods: We retrospectively analysed patients diagnosed with GIM or GA in three centers in The Netherlands and UK between 2012 and 2019. Cases with GIM and/or GA diagnosis at index endoscopy were retrieved through systematic search of pathology databases using ‘gastric’ and ‘intestinal metaplasia’ or ‘atrophy’ keywords. Endoscopy reports were analysed to ascertain accuracy of endoscopic diagnoses. Adequacy of surveillance was assessed following histological diagnosis at the index endoscopy based on ESGE guidelines published in 2012. Results: We included 396 patients with a median follow-up of 57.2 months. Mean age was 66 years and the rates of antrum-predominant versus extensive GIM were comparable (37% vs 38%). Endoscopic recognition rates were 48.5% for GA and 16.3% for GIM. Surveillance was adequately carried out in 215 of 396 patients (54.3%). Conclusion: In countries with a low incidence of GAC, the rate of endoscopic recognition of gastric pre-cancerous lesions and adherence to surveillance recommendation are low. Substantial improvement is required in endoscopic training and awareness of guidelines recommendation in order to optimise detection and management of pre-malignant gastric conditions.
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 16 (6) , 313-320
Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework
Barrett's esophagus is a precancerous condition that can progress in a stepwise manner to dysplasia and eventually esophageal adenocarcinoma (EAC). Once diagnosed, patients with Barrett's esophagus are kept on surveillance to detect progression so that timely intervention can occur with endoscopic therapy. Several demographic and clinical risk factors are known to increase progression toward EAC, such as longer Barrett's segments, and these patients are kept on tighter surveillance. While p53 IHC has been advocated as an adjunct to histopathologic diagnosis, use of this biomarker is variable, and no other molecular factors are currently applied. Given the new evidence available, it is time to consider whether other risk factors or tools could be applied in clinical practice to decide on closer or attenuated surveillance. In this commentary, we summarize the most relevant risk factors for Barrett's esophagus progression, highlight the most promising novel risk stratification tools—including nonendoscopic triage and commercial biomarker panels, and propose a new framework suggesting how to incorporate risk stratification into clinical practice.
- 1 June 2023
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 16 (6) , 313-320
Open AccessCategorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework
Barrett's esophagus is a precancerous condition that can progress in a stepwise manner to dysplasia and eventually esophageal adenocarcinoma (EAC). Once diagnosed, patients with Barrett's esophagus are kept on surveillance to detect progression so that timely intervention can occur with endoscopic therapy. Several demographic and clinical risk factors are known to increase progression toward EAC, such as longer Barrett's segments, and these patients are kept on tighter surveillance. While p53 IHC has been advocated as an adjunct to histopathologic diagnosis, use of this biomarker is variable, and no other molecular factors are currently applied. Given the new evidence available, it is time to consider whether other risk factors or tools could be applied in clinical practice to decide on closer or attenuated surveillance. In this commentary, we summarize the most relevant risk factors for Barrett's esophagus progression, highlight the most promising novel risk stratification tools—including nonendoscopic triage and commercial biomarker panels, and propose a new framework suggesting how to incorporate risk stratification into clinical practice.
- Open Access
- 9 December 2022
- Published by Elsevier in The Lancet Oncology
- Vol. 24 (1) , 107-116
Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study
- 9 December 2022
- Published by Elsevier in The Lancet Oncology
- Vol. 24 (1) , 107-116
Open AccessEndoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study